Potential of adenosine A(2A) receptor antagonists in the treatment of movement disorders

CNS Drugs

Volumn 10, Issue 5, 1998, Pages 311-320

  Mally, Judit ^a   Stone, Trevor W ^b,c  

^a Erszebet Korhaz ^*  (Hungary)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (3 PHENYLPROPYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ISTRADEFYLLINE; UNCLASSIFIED DRUG;

DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; HUMAN; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031756703     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810050-00001     Document Type: Review

References (95)

1. Stone TW, Newby AC, Lloyd HGE. Adenosine release. In: Williams M, editor. Adenosine and adenosine receptors. New York: Humana Press, 1990: 173-224
2. Stone TW, editor. Adenosine in the nervous system. London: Academic Press, 1991
3. Stone TW, Simmonds HA. Purines: basic and clinical aspects. Dordrecht: Kluwer Press, 1991
4. Jarvis MF, Williams M. Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2 selective agonist [3H]-CGS 21680. Eur J Pharmacol 1989; 168: 243-6
5. Jarvis MF, Jackson RH, Williams M. Autoradiographic characterization of high-affinity adenosine A2 receptors in the rat brain. Brain Res 1989; 484: 111-8
6. 2A receptors in the rat hippocampus. Brain Res 1994; 649: 208-16
7. Kirk IP, Richardson PJ. Further characterization of [3H]-CGS 21680 binding sites in the rat striatum and cortex. Br J Pharmacol 1995; 114: 537-43
8. Johansson B, Georgiev V, Parkinson FE, et al. The binding of the adenosine A2 receptor selective agonist [H3]CGS21680 to rat cortex differs from its binding to rat striatum. Eur J Pharmacol 1993; 247: 103-10
9. 2A receptors. Naunyn Schmiedebergs Arch Pharmacol 1996; 353: 261-71
10. Lindstrom K, Ongini E, Fredholm BB. The selective adenosine A2A receptor antagonist SCH58261 discriminates between two different binding sites for [3H]CGS21680 in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1996; 354: 539-41
11. Le F, Townsend-Nicholson A, Baker E, et al. Characterisation and chromosomal localisation of the human A2A adenosine receptor gene: ADORA2A. Biochem Biophys Res Commun 1996; 2: 461-7
12. Braun S, Levitzki A. Adenosine receptor permanently coupled to turkey erythrocyte adenylate cyclase. Biochemistry 1979; 18: 2134-8
13. Alexander SPH, Reddington M. The cellular localisation of adenosine receptors in rat neostriatum. Neuroscicnce 1989; 28: 645-51
14. 2A adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons. Brain Res 1993; 631: 161-6
15. James S, Xuereb JH, Askalan R, et al. Adenosine receptors in post-mortem human brain. Br J Pharmacol 1992; 105: 238-44
16. Schiffman SN, Libert F, Vassart G, et al. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett 1991; 130: 177-81
17. Mally J, Stone TW. The effect of theophylline on essential tremor: the possible role of GABA. Pharmacol Biochem Behav 1991; 39: 345-9
18. Svenningsson P, Le Moine S, Kull B, et al. Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscicnce 1997; 80: 1171-85
19. Ameri A, Jurna I. Adenosine A1 and non-A1 receptors: intracellular analysis of the actions of adenosine agonists and antagonists in rat hippocampal neurones. Brain Res 1991; 546: 69-78
20. Thompson SM, Haas HL, Gahwiler BH. Comparisons of the actions of adenosine at pre- and postsynaptic receptors in the rat hippocampus in vitro. J Physiol 1992; 451: 347-63
21. Vizi ES, Knoll J. The inhibitory effect of adenosine and related nucleotides on the release of acetylcholine. Neuroscience 1976; 1: 391-8
22. Michaelis ML, Michaelis EK, Myers SL. Adenosine modulation of synaptosomal dopamine release. Life Sci 1979; 24: 2083-92
23. Zetterstrom T, Fillenz M. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur J Pharmacol 1990; 180: 137-43
24. Jin S, Johansson B, Fredholm BB. Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J Pharmacol Exp Ther 1993; 267: 801-8
25. Correiadesa P, Sebastiao AM, Ribeiro JA. Inhibitory and excitatory effects of adenosine receptor agonists on evoked transmitter release from phrenic nerve endings of the rat. Br J Pharmacol 1991; 103: 1614-20
26. Kirkpatrick KA, Richardson PJ. Adenosine receptor mediated modulation of acetylcholine release from rat striatal synaptosomes. Br J Pharmacol 1993; 110: 949-54
27. 2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci Lett 1995; 196: 41-4
28. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 1995; 287: 215-7
29. Sebastiao AM, Ribeiro JA. Adenosine A2 receptor mediated excitatory actions on the nervous system. Prog Neurobiol 1996; 48: 167-89
30. 2A receptor mediated modulation of striatal Gaba and acetylcholine release. Br J Pharmacol 1994; 113: 43-8
31. Jin S, Fredholm BB. Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect caetcholamine release. Naunyn Schmiedeberg Arch Pharmacol 1997; 355: 48-56
32. Richardson PJ, Dixon AK, Gubitz A, et al. Control of striatal gene expression and transmitter release by the adenosine A2A receptor antagonist KF17837 [abstract]. Mov Disord 1997; 12 Suppl. 1: 122
33. Fuxe K, Li XM, Hedlund F, et al. Integrative aspects of brain function: receptor-receptor interactions in dopamine transmission of the basal ganglia. In: Stone TW, editor. CNS neurotransmitters and neuromodulalors - dopamine. Boca Raton (FL): CRC Press, 1996: 89-106
34. Ferre S, Fredholm BB, Morelli M, et al. Adenosine-dopamine receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997; 20: 482-7
35. Schiffmann SN, Jacobs O, Vanderhaeghen J-J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991; 57: 1062-7
36. Ferre S, Euler G, Johansson B, et al. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci 1991; 88: 7238-41
37. Morelli M, Fenu S, Pinna A, et al. Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 1994; 251: 21-5
38. Josselyn SA, Beninger RJ. Behavioral effects of intrastriatal caffeine mediated by adenosinergic modulation of dopamine. Pharmacol Biochem Behav 1991; 39: 97-103
39. Ferre S, O'Connor WT, Fuxe K, et al. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 1993; 13: 5402-6
40. Ferre S, OConnor WT, Snaprud P, et al. Antagonistic interaction between adenosine A2 receptors and dopamine D2 receptors in the ventral striopallidal system: implications for the treatment of schizophrenia. Neuroscience 1994; 63: 765-73
41. Ferre S, Schwarcz R, Li XL, et al. Chronic haloperidol treatment lead to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Psychopharmacology 1994; 116: 279-84
42. Ferre S, Fuxe K. Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Res 1992; 594: 124-30
43. Sattin A, Rall TW. The effect of adenosine and adenine nucleotides on the cyclic AMP content of guinea-pig cerebral cortex slices. Mol Pharmacol 1970; 6: 13-20
44. Stone TW. Purine receptors and their pharmacological potential. Adv Drug Res 1989; 18: 292-429
45. 1-seleclive adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch Pharmacol 1987; 335: 59-63
46. 2A adenosine receptor antagonisis. Curr Med Chem 1995; 2: 707-22
47. Shimada J, Koike N, Nonaka H, et al. Adenosine A2 antagonists with potent anticataleplic activity. Bioorg Med Chem Lett 1997; 7: 2349-52
48. Nonaka H, Ichimura M, Takeda M, et al. KF 17837 ((E)-8-(3,4-dimethoxystyryl )-1,3-dipropyl-7-methylxanthine) a potent and selective adenosine A2 receptor antagonist. Eur J Pharmacol 1994; 267: 335-41
49. 2A antagonist. Appl Radiat Isot 1996; 47: 507-11
50. 11C-KF17837 using 3D-PET. Nucl Med Biol 1997; 24: 187-91
51. 2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 1994; 256: 263-8
52. Nonaka H, Saki M, Ichimura M, et al. Novel potent A2A adenosine receptor antagonists [abstract]. Mov Disord 1997; 12 Suppl. 1: 120
53. Williams M. Adenosine receptor agonists and antagonists. In: Stone TW, editor. Adenosine in the nervous system. London: Academic Press, 1991: 137-72
54. 2A receptors. Drug Dev Res 1996; 39: 450-60
55. 2A selective adenosine receptor antagonist. Br J Pharmacol 1995; 115: 1096-102
56. Keddie JR, Poucher SM, Shaw GR, et al. In vivo characterisation of ZM241385, a selective adenosine A2A receptor antagonist. Eur J Pharmacol 1996; 301: 107-13
57. 2A adenosine receptor antagonists. Bioorg Med Chem Lett 1994; 4: 2539-44
58. 2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 1996; 117: 1381-6
59. 2A adenosine receptor antagonist. J Pharmacol Exp Ther 1996; 276: 398-404
60. 2A adenosine receptor antagonist. Drug Dev Res 1997; 42: 63-70
61. Dionisotti S, Ongini E, Zocchi C, et al. Characterisation of human A2A adenosine receptors using the antagonist radioligand [3H]|SCH58261. Br J Phannacol 1997; 121: 353-60
62. Shimada J, Suzuki F, Nonaka H, et al. (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem 1992; 35: 2342-5
63. Nonaka H, Mori A, Ichimura M, et al. Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes. Mol Pharmacol 1994; 46: 817-22
64. Fredholm BB, Lindstrom K, Dionisotti S, et al. [3H]SCH58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies. J Neurochem 1998; 70: 1210-6
65. Baraldi PG, Cacciari B, Spalluto G, et al. Pyrazolo[4,3e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A2A adenosine antagonists. J Med Chem 1996; 39: 1164-71
66. Jacobson KA, Gallo-Rodriguez C, Melman N, et al. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem 1993; 36: 1333-42
67. Green RD, Proudfit HK, Yeung SH. Modulation of striatal dopaminergic function by local injection of 5′-N-ethylcarboxamide adenosine. Science 1982; 218: 58-60
68. Vellucci SV, Sirinathsinghji DJS, Richardson PJ. Adenosine A2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology 1993; 111: 383-8
69. Brown SJ, Gill R, Eveneden JL, et al. Striatal A2 receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation. Psychopharmacology 1991; 103: 78-82
70. 2A receptors in the rat striatum induced catalepsy that is reversed by antagonists of NMDA receptors. Neurosci Lett 1995; 196: 1-4
71. 2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 1996; 295: 147-54
72. 2A receptor-mediated modulation of contracteral rotation induced by metabotropic glutamate receptor activation. Eur J Pharmacol 1995; 287: 115-20
73. Durcan MJ, Morgan PF. NECA-induced by pomotility in mice: evidence for a predominantly central site of action. Pharmacol Biochem Behav 1989; 32: 487-90
74. Janusz CA, Berman RF. The A2 adenosine selective analog CGS21680 depresses locomotor activity but does not block amygdala-kindled seizures in rats. Neurosci Lett 1992; 141: 247-50
75. 2A receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull 1993; 31: 397-404
76. Sandor NT, Kiss J, Sando A, et al. Naloxone enhances the release of acethylcholine from cholinergic interneurones of the striatum if dopaminergic input is impaired. Brain Res 1991; 552: 343-5
77. Ferre S, Herrera-Marschitz M, Grabowska-Anden M, et al. Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur J Pharmacol 1991; 192: 36-40
78. Jiang H, Jackson-Lewis V, Muthane U, et al. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behaviour in 6-hydroxvdopamine-lesioned rats. Brain Res 1993; 613: 347-51
79. Popoli P, Pezzola A, Scotti DeCarolis A. Modulation of striatal adenosine A1 and A2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats. Eur J Pharmacol 1994; 257: 21-5
80. 2A adenosine receptors positively modulates turning behaviour and C-fos expression induced by D1 agonists in dopamine denervated rats. Eur J Neurosci 1996; 8: 1176-81
81. Mandhane SN, Chopde CT, Ghosh AK. Adenosine A2 receptors modulate haloperidol induced catalepsy in rats. Eur J Pharmacol 1997; 328: 135-41
82. Pollack AE, Fink JS. Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behaviour and striatal c-fos induction in 6-hydroxydopamine-lesioned rats. Brain Res 1996; 743: 124-30
83. Fenu S, Pinna A, Ongini E, et al. Adenosine A2A receptor antagonism potentiates L-DOPA induced turning behaviour and c-fos expression in 6-hydroxydopamine lesioned rats. Eur J Pharmacol 1997; 321: 143-7
84. Morelli M, Pinna A, Wardas J, et al. Adenosine A2 receptors stimulate c-fos expression in striatal neurones of 6-hydroxydopamine-lesioned rats. Neuroscience 1996; 67: 49-55
85. Garrett BE, Holtzman SG. D1 and D2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats. Pharmacol Biochem Behav 1994; 47: 89-94
86. Kuwana Y, Shiozaki S, Kanda T, et al. A2A adenosine receptor antagonists are antiparkinsonian in animal models [abstract]. Soc Neurosci Abst 1997; 23: 237
87. Grondin R, Tahar AH, Gregoire L, et al. Potential use of the selective adenosine A2a receptor antagonist KW-6002 in Parkinson's disease [abstract]. Soc Neurosci Abst 1997; 23: 1902
88. Mally J, Stone TW. The effect of theophylline on parkinsonian symptoms. J Pharm Pharmacol 1994; 46: 515-7
89. Martinez-Mir MI, Probst A, Palacio, JM. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991; 42: 697-706
90. Mally J. Aminophylline and essential tremor. Lancet 1989; 1: 278-9
91. Mally J. Effect of low dose theophylline therapy on essential tremor. N Trend Clin Neuropharmacol 1988; 11: 51-5
92. Mally J, Stone TW. Efficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placeho and propranolol. J Neurol Sci 1995; 132: 129-32
93. Mally J, Stone TW. Potential role of adenosine antagonist therapy in pathological tremor disorders. Pharmacol Ther 1996; 72: 243-50
94. 2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 1997; 17: 82-91
95. Norenberg W, Wirkner K, Illes P. Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones. Br J Pharmacol 1997; 122: 71-80